{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 49 of 169', '26. Any clinically significant abnormal findings in physical examination, vital signs,', 'electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during the', 'screening period, which in the opinion of the investigator, may put the subject at risk', 'because of his/her participation in the trial, or may influence the results of the trial, or', \"the subject's ability to complete entire duration of the trial.\", '27. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level >2.0 times', 'the ULN (upper limit of normal) at screening.', '28. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),', 'hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology', 'at screening. Subjects with positive HBsAb may be randomised provided they are', 'hepatitis B vaccinated and have negative HBsAg and HBcAb.', '29. Subjects who are not willing to abstain from donating blood and/or plasma from the', 'time of informed consent and for 16 weeks (5 half-lives) after last dose of IMP.', '30. Subjects who are legally institutionalised.', '31. Pregnant, breastfeeding, or lactating women.', '32. Employees of the trial site or any other individuals directly involved with the planning', 'or conduct of the trial, or immediate family members of such individuals.', '8.4 Screening, screening failures, and randomisation', 'Trial participation begins once written informed consent is obtained (see Appendix 4B for', 'details on the informed consent process). Once informed consent is obtained, a subject', 'identification number (subject ID) will be assigned by a central interactive web response', 'system (IWRS) and the screening evaluations to assess eligibility criteria may begin. The', 'subject ID will be used to identify the subject during the screening process and throughout', 'trial participation, if applicable. A master log of all consented subjects will be maintained at', 'the trial site.', 'Screening failures are defined as subjects who consent to participate in the trial but are not', 'subsequently randomly assigned to trial treatment. A minimal set of screening failure', 'information is required to ensure transparent reporting of screening failure subjects to meet', 'the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements (27)', 'and to respond to queries from regulatory authorities. Minimal information includes', 'demography, screening failure details, eligibility criteria, and any adverse events (AEs) and', 'serious AEs (SAEs). Follow-up of SAEs must be carried out according to Section 11.6.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 50 of 169', 'Individuals who do not meet the criteria for participation in this trial (screening failures) may', 'not be re-screened. However, if the reason for screening failure is administrative and not due', 'to the subject failing to meet the eligibility criteria, re-screening may be permitted (this will', \"require approval by the sponsor's medical expert after thorough review of all data from the\", 'original screening visit in the electronic case report form [eCRF]). Individuals who are', 're-screened will get a new subject ID.', 'The investigator will maintain a list of all randomised subjects at the trial site including each', \"subject's identity, date of enrolment and corresponding subject ID so that any subject may be\", 'identified if required for any reason. The list must not be copied or retained by LEO.', 'Note that enrolment is defined as the period from screening to randomisation (i.e., subjects are', 'not enrolled until randomised) (27).', '8.5 Discontinuation', 'A subject may withdraw from trial or from treatment at any time (prior to first dose or during', 'treatment period) at his/her own request. A subject may be withdrawn at any time at the', 'discretion of the investigator. Discontinued subjects will not be replaced.', 'Medical reasons for permanent discontinuation of IMP are given in Section 9.8.1.', 'Assessments', 'Subjects who permanently discontinue IMP for any reason will be asked to attend an early', 'termination visit and return to the trial site for 1 or 2 additional visits as indicated below', 'depending on the time of discontinuation of IMP (see the SoP [Section 4] for data to be', 'collected at these visits). The investigator will review any AEs which will be followed-up', 'according to Section 11.6, if the subject agrees.', 'Subjects who permanently discontinue IMP prior to Week 16 will be asked to attend:', 'Early termination visit.', 'Nominal Week 16 visit (16 weeks after randomisation).', 'Safety follow-up visit (16 weeks after last administration of IMP).', 'Subjects who permanently discontinue IMP at Week 16 or after Week 16 will be asked to', 'attend:', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}